Hongchuan Jiang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4267980/publications.pdf

Version: 2024-02-01

1305906 939365 23 342 8 18 citations g-index h-index papers 25 25 25 570 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Single-Nucleotide Polymorphisms in LEP and LEPR Associated With Breast Cancer Risk: Results From a Multicenter Case–Control Study in Chinese Females. Frontiers in Oncology, 2022, 12, 809570.	1.3	1
2	Abstract OT1-12-06: Neoadjuvant pyrotinib versus pertuzumab in combination with trastuzumab and nab-Paclitaxel for patients with HER2-positive early or locally advanced breast cancer (Pyramid): A randomized, multicenter, open-label, phase 2 trial. Cancer Research, 2022, 82, OT1-12-06-OT1-12-06.	0.4	0
3	Multi-center investigation of breast reconstruction after mastectomy from Chinese Society of Breast Surgery: A survey based on 31 tertiary hospitals (CSBrS-004). Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 33-41.	0.7	6
4	MicroRNA‑598 inhibits the growth of triple negative breast cancer cells by targeting JAG1. Experimental and Therapeutic Medicine, 2021, 21, 235.	0.8	3
5	Diagnostic value of sialylâ€Tn immunocytochemistry in breast cancer presenting with pathological nipple discharge. Cancer Medicine, 2021, 10, 1783-1790.	1.3	2
6	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer. Gland Surgery, 2021, 10, 2159-2169.	0.5	4
7	Diagnostic accuracy and prognostic value of three-dimensional electrical impedance tomography imaging in patients with breast cancer. Gland Surgery, 2021, 10, 2673-2685.	0.5	7
8	Predicting Axillary Lymph Node Metastasis in Early Breast Cancer Using Deep Learning on Primary Tumor Biopsy Slides. Frontiers in Oncology, 2021, 11, 759007.	1.3	20
9	Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study. BMC Cancer, 2021, 21, 1301.	1.1	13
10	<p>Demethylation of the Cosmc Promoter Alleviates the Progression of Breast Cancer Through Downregulation of the Tn and Sialyl-Tn Antigens</p> . Cancer Management and Research, 2020, Volume 12, 1017-1027.	0.9	8
11	miRâ€511 inhibits proliferation and metastasis of breast cancer cells by targeting FGF4. Journal of Gene Medicine, 2020, 22, e3168.	1.4	8
12	Overexpression of Cosmc suppresses cell migration and invasion in different subtypes of breast cancer cells via Tn and T glycans. Bioscience Reports, 2020, 40, .	1.1	5
13	Use of fiberoductoscopy for the management of pathological nipple discharge: ten years follow up of a single center in China. Gland Surgery, 2020, 9, 2035-2043.	0.5	5
14	Association of PTPN1 polymorphisms with breast cancer risk: A caseâ€control study in Chinese females. Journal of Cellular Biochemistry, 2019, 120, 12039-12050.	1.2	6
15	Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women. Frontiers in Endocrinology, 2019, 10, 905.	1.5	15
16	Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miRâ€'33aâ€'5pâ€'LDHA axis. Molecular Medicine Reports, 2019, 20, 1857-1865.	1.1	10
17	Comparison of surgical complication between immediate implant and autologous breast reconstruction after mastectomy: A multicenter study of 426 cases. Journal of Surgical Oncology, 2018, 118, 953-958.	0.8	24
18	MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3. Biomedicine and Pharmacotherapy, 2018, 103, 1482-1489.	2.5	77

#	Article	IF	CITATIONS
19	Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention. Oncologist, 2017, 22, 1431-1443.	1.9	39
20	Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis. Oncotarget, 2017, 8, 6003-6012.	0.8	30
21	Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study. Health and Quality of Life Outcomes, 2016, 14, 51.	1.0	8
22	Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/AKT pathway and suppresses breast cancer growth. OncoTargets and Therapy, 2015, 8, 427.	1.0	50
23	Multicenter prospective study of magnetic resonance imaging prior to breast-conserving surgery for breast cancer. Chinese Medical Journal, 2014, 127, 2401-6.	0.9	1